Progression of Clinical and Eye Movement Markers in Preataxic Carriers of Machado-Joseph Disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov Disord Subsets: MEDLINE
    • Publication Information:
      Publication: <2001->: New York, NY : Wiley-Liss
      Original Publication: [New York, N.Y.] : Raven Press, [c1986-
    • Subject Terms:
      Machado-Joseph Disease*/diagnosis ; Machado-Joseph Disease*/genetics ; Spinocerebellar Ataxias*/diagnosis ; Spinocerebellar Ataxias*/genetics; Adult ; Humans ; Eye Movements ; Heterozygote ; Severity of Illness Index ; Disease Progression
    • Abstract:
      Background: Little is known about preclinical stages of Machado-Joseph disease, a polyglutamine disorder characterized by progressive adult-onset ataxia.
      Objective: We aimed to describe the longitudinal progression of clinical and oculomotor variables in the preataxic phase of disease.
      Methods: Carriers and noncarriers were assessed at three visits. Preataxic carriers (Scale for Assessment and Rating of Ataxia score < 3) expected to start ataxia in ≤4 years were considered near onset (PAN). Progressions of ataxic and preataxic carriers, considering status at the end of the study, were described according to the start (or its prediction) of gait ataxia (TimeToAfterOnset) and according to the study time.
      Results: A total of 35 ataxics, 38 preataxics, and 22 noncarriers were included. The "TimeToAfterOnset" timeline showed that Neurological Examination Scale for Spinocerebellar Ataxias (NESSCA; effect size, 0.09), Inventory of Non-Ataxia Symptoms (INAS0.07), and the vestibulo-ocular reflex gain (0.12) progressed in preataxic carriers, and that most slopes accelerate in PAN, turning similar to those of ataxics. In the study time, NESSCA (1.36) and vertical pursuit gain (1.17) significantly worsened in PAN, and 6 of 11 PANs converted to ataxia. For a clinical trial with 80% power and 2-year duration, 57 PANs are needed in each study arm to detect a 50% reduction in the conversion rate.
      Conclusions: NESSCA, INAS, vestibulo-ocular reflex, and vertical pursuit gains significantly worsened in the preataxic phase. The "TimeToAfterOnset" timeline unveiled that slopes of most variables are small in preataxics but increase and reach the ataxic slopes from 4 years before the onset of ataxia. For future trials in preataxic carriers, we recommend recruiting PANs and using the conversion rate as the primary outcome. © 2022 International Parkinson and Movement Disorder Society.
      (© 2022 International Parkinson and Movement Disorder Society.)
    • References:
      Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8(3):221-228.
      Saute JAM, Jardim LB. Machado Joseph disease: clinical and genetic aspects, and current treatment. Expert Opin Orphan Drugs 2015;3:517-535.
      Ashizawa T, Öz G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol 2018;14(10):590-605. Review. Erratum in: Nat Rev Neurol. 2018 Dec;14(12):749.
      Jacobi H, du Montcel ST, Bauer P, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol 2015;14(11):1101-1108.
      Diallo A, Jacobi H, Tezenas du Montcel S, Klockgether T. Natural History of Most Common Spinocerebellar Ataxia: A Systematic Review and Meta-Analysis. J Neurol 2021;268:2749-2756. https://doi.org/10.1007/s00415-020-09815-2.
      Leotti VB, de Vries JJ, Oliveira CM, et al. CAG repeat size influences the progression rate of spinocerebellar ataxia type 3. Ann Neurol 2021;89(1):66-73.
      Jacobi H, du Montcel ST, Romanzetti S, et al. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurol 2020;19(9):738-747.
      de Oliveira CM, Leotti VB, Bolzan G, et al. Pre-ataxic changes of clinical scales and eye movement in Machado-Joseph disease: BIGPRO study. Mov Disord 2021;36(4):985-994.
      Gordon CR, Joffe V, Vainstein G, Gadoth N. Vestibulo-ocular areflexia in families with spinocerebellar ataxia type 3 (Machado-Joseph disease). J Neurol Neurosurg Psychiatry 2003;74(10):1403-1406.
      Moscovich M, Okun MS, Favilla C, et al. Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study. J Neuroophthalmol 2015;35(1):16-21.
      Luis L, Costa J, Muñoz E, et al. Vestibulo-ocular reflex dynamics with head-impulses discriminates spinocerebellar ataxias types 1, 2 and 3 and Friedreich ataxia. J Vestib Res 2016;26(3):327-334.
      Lemos J, Novo A, Duque C, et al. Static and Dynamic Ocular Motor Abnormalities as Potential Biomarkers in Spinocerebellar Ataxia Type 3. Cerebellum 2021;20(3):402-409.
      Raposo M, Vasconcelos J, Bettencourt C, et al. Nystagmus as an early ocular alteration in Machado-Joseph disease (MJD/SCA3). BMC Neurol 2014;22(14):17.
      Wu C, Chen DB, Feng L, et al. Oculomotor deficits in spinocerebellar ataxia type 3: Potential biomarkers of preclinical detection and disease progression. CNS Neurosci Ther 2017;23(4):321-328.
      Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66(11):1717-1720.
      Kieling C, Rieder CR, Silva AC, et al. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15(4):371-376.
      Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145(2):205-211.
      Schmitz-Hübsch T, Giunti P, Stephenson DA, et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 2008;71(7):486-492.
      Tezenas du Montcel S, Charles P, Ribai P, et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 2008;131(Pt 5):1352-1361.
      Schmitz-Hübsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 2008;71(13):982-989.
      Bahill AT, Clark MR, Stark L. The main sequence, a tool for studying human eye movements. Math Biosci 1975;24:191-204.
      de Mattos EP, Leotti VB, Soong BW, et al. Age at onset prediction in spinocerebellar ataxia type 3 changes according to population of origin. Eur J Neurol 2019 Jan;26(1):113-120.
      Lenth R. _emmeans: Estimated Marginal Means, aka Least-Squares Means_. R package version 1.7.4-1. https://CRAN.R-project.org/package=emmeans, 2022.
      Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.
      Borges R, Mancuso A, Camey S, et al. Power and Sample Size for Health Researchers: uma ferramenta para cálculo de tamanho amostral e poder do teste voltado a pesquisadores da área da saúde. Clin Biomed Res 2020;40(4):247-253 Retrieved fromhttps://seer.ufrgs.br/hcpa/article/view/109542.
      Donohue MC. Longpower: Power and sample size calculations for longitudinal data. 2021. R package version 1.0.23.
      Schmitz-Hübsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010;74(8):678-684.
      Saute JA, Donis KC, Serrano-Munuera C, et al. Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials. Cerebellum 2012;11(2):488-504.
      Tezenas du Montcel S, Charles P, Goizet C, Marelli C, Ribai P, et al. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia. Arch Neurol 2012;69(4):500-508.
      Piccinin CC, Rezende TJR, de Paiva JLR, et al. A 5-Year Longitudinal Clinical and Magnetic Resonance Imaging Study in Spinocerebellar Ataxia Type 3. Mov Disord 2020;35(9):1679-1684.
      Bateman RJ, Benzinger TL, Berry S, et al. DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 2017;13(1):8-19.
      Wang G, Berry S, Xiong C, et al. Dominantly inherited Alzheimer Network Trials Unit. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med 2018;37(21):3047-3055.
      Ahamadi M, Conrado DJ, Macha S, et al. Critical path for Parkinson's (CPP) consortium. development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson's disease to inform clinical trial designs. Clin Pharmacol Ther 2020;107(3):553-562. https://doi.org/10.1002/cpt.1634.
      Mohan A, Sun Z, Ghosh S, et al. A machine-learning derived Huntington's disease progression model: insights for clinical trial design. Mov Disord 2022;37(3):553-562.
      Fouarge E, Monseur A, Boulanger B, et al. NatHis-MTM Study Group. Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy. Orphanet J Rare Dis 2021;16(1):3.
      Schulte T, Mattern R, Berger K, et al. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001;58(9):1451-1457.
      Monte TL, Rieder CR, Tort AB, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003;107(3):207-210.
      Saute JA, de Castilhos RM, Monte TL, et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 2014;29(4):568-573.
      Maas RPPWM, Toni I, Doorduin J, et al. Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study. BMC Neurol 2019;19(1):149.
    • Contributed Indexing:
      Keywords: Machado-Joseph disease; clinical scales; preataxic period; spinocerebellar ataxia type 3; video-oculography
    • Publication Date:
      Date Created: 20220921 Date Completed: 20230120 Latest Revision: 20230222
    • Publication Date:
      20231215
    • Accession Number:
      10.1002/mds.29226
    • Accession Number:
      36129443